治疗高血脂症的新型PPARα激动剂Pemafibrate  

Pemafibrate as a highly effective PPAR-α agonist treating hyperlipidemia

作　　者：万蒞 WAN Li(Department of Pharmacy, Hubei＇s maternal and child health hospital, Wuhan 430000, China)

机构地区：[1]湖北省妇幼保健院药剂科,湖北武汉430070

出　　处：《药物评价研究》2018年第8期1562-1564,共3页Drug Evaluation Research

摘　　要：Pemafibrate(Parmodia?)是高效的过氧化物酶体增殖激活受体α(PPARα)激动剂,通过选择性结合PPARα受体调控PPARα的表达,从而增加高密度脂蛋白的含量和降低血浆中的三酰甘油水平。该药由日本兴和集团研制,并在2017年7月3日被批准上市,在日本用于治疗高血脂症。就Pemafibrate的化学性质、作用机制、药动学和临床研究等进行概述,以期为临床用药提供帮助。Pemafibrate（Parmodia？） is a novel, highly selective peroxisome proliferator-activated receptor（PPAR）-α agonist. It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metabolism, thereby leading the reduced plasma triglyceride levels and the increased high-density lipoprotein cholesterol levels. Oral pemafibrate developed by Kowa Company has been approved in Japan on July 3, 2017 for the treatment of hyperlipidemia. The properties, pharmacokinetics, pharmacodynamics, and clinical trials about pemafibrate in the review are introduced to guide the doctors and the patients.

关 键 词：pemafibrate 过氧化物酶体增殖激活受体α激动剂 高血脂症 

分 类 号：R972.6[医药卫生—药品]